Biosecurity laws under scanner

DSC_0674 (2)India tabled an Agriculture Biosecurity Bill in Parliament last year (2013). The government at the Centre has changed since and the Bill is still pending. In the absence of a robust national regulation for biosecurity, the country is still dependent upon an archaic Destructive Insects and Pests Act (DIPA) and the Livestock Importation Act.

In a commentary that discusses the urgent need for a new regulation for the country, our freelance contributor Manupriya writes:

One of the biggest criticisms about the Bill is that it does not include epizootics/zoonoses, disease causing organisms that can hop from one vertebrate to another. Famous examples of such diseases are SARS, Avian flu and Mad Cow disease which can be easily transferred from their primary hosts to humans. While mad cow has not been a cause of concern yet for India, both SARS and avian flu have caused havoc.

India’s ministry of Health and Family Welfare has not made any input to the Bill saying it is the prerogative of the Food safety and Standards authority of India Act. However, international guidelines on biosecurity laid out by FAO clearly say that human health is a key factor that should be considered in every country’s biosecurity framework.

Another criticism for the Bill has been in the area of domestic quarantine. While the bill, does forbid individuals to “possess, move, grow, raise, culture, breed or produce any plant, animal and plant product”, it does not clarify how states should act to contain the spread of disease. India’s past record in imposing domestic quarantine has not been worth mention. Numerous diseases that made a localized appearance earlier have now spread all over the country.

The new Bill hopes to establish an Agricultural Biosecurity Authority of India with headquarters in the national capital region and regional centres all over the country. The authority is expected to be responsible for regulation of the import and export of plants, animals and related products; prevention of entry of quarantine pests; and implementation of post-entry quarantine measures.

Read the commentary here for more on the whys and hows of biosafety in India.

NIH responds to criticism over handling of flu papers

The US National Institutes of Health (NIH) today released a response to a sharply worded internal criticism about the handling of two controversial H5N1 avian influenza papers, one of which was published in Nature yesterday.

The criticism came from Michael Osterholm, a public-health researcher and member of the National Science Advisory Board for Biosecurity (NSABB), which had been asked to advise the government on the potential biosecurity risks of publishing the papers in full. After an initial unanimous recommendation to redact the papers, the 22 voting members of NSABB were called back to the NIH campus to re-evaluate the decision in light of additional information and revisions to the papers. This time it voted in favour of publication, but six members of the NSABB, including Osterholm, dissented on the publication of one of the manuscripts.

Osterholm’s letter, which was leaked to Science and Nature, called the proceedings of this meeting, held 29–30 March, biased and incomplete, presenting an argument with the express purpose of getting the papers published.

In a six-page response — released today, but dated 25 April — Amy Patterson, an NIH official who manages the NSABB, responded to Osterholm’s critiques point by point. She writes that the views and perspectives that Osterholm claims were lacking at the meeting were in fact presented, by Osterholm himself. She says that he did not provide recommendations for experts to speak at the meeting. (In his letter, Osterholm said, “I personally tried to have their voices represented at the meeting. They were not invited.”) And she notes that although she respects his opinions and perspectives, “I do believe that some of them were based in part on a misunderstanding of the facts.”

Interestingly, Patterson notes that the US government is now looking into ways to allow “controlled access to sensitive scientific information for those with a legitimate need to know, in cases where certain details are redacted from a manuscript.” This is a mechanism that many members in the NSABB have been calling for, but one that obviously wasn’t ready for the H5N1 papers. Many in the scientific community worry that this redaction process is tantamount to censorship and that it has delicate political implications internationally. Without involvement from the rest of the world, it could seem that the United States or a handful of developed countries are attempting to unilaterally control the release of potentially dangerous information.

Senate Hearing on H5N1 papers exposes political divisions

26 April in Washington DC, US Senator Joseph Lieberman of Connecticut revealed that his grandmother was killed by influenza during the 1918 pandemic. This was one reason he has been so interested in a pair of yet-to-be-published papers on laboratory-created H5N1 avian influenza strains that could conceivably prove many times more deadly than the 1918 flu. The other reason for his interest is that he chairs the committee on Homeland Security and Government Affairs, which had called a hearing to understand how decisions were made about the research’s potential use as an agent of bioterrorism. At the hearing, officials involved in making the decision to publish the research were queried about a letter that was leaked to the press two weeks ago. In the letter, Michael Osterholm, a member of the National Science Advisory Board for Biosecurity (NSABB), accused the U.S. government of stacking the decks in favour of full publication during a crucial closed door meeting in March at which the NSABB was asked to re-evaluate the papers.

Paul Keim, acting chair of the NSABB, who testified today, said “I view it as a very constructive type of communication. It was unfortunate that it was leaked to the public… that made it very hard to have a constructive conversation about it.” He went on to say that he agreed with Osterholm’s contention that there was a bias in the list of witnesses presenting evidence for and against full publication. The presenters included the two researchers whose teams had performed the research and one of their collaborators. “But the bias inherent in these witnesses was not very important,” Keim says, noting that the board members were able to ask them tough, probing questions. Continue reading